A multimodal approach in the treatment of chronic cerebral ischemia: what should a doctor know?

The article discusses one of the leading problems of modern angioneurology - chronic cerebral ischemia. The main etiological factors playing a significant role in the development of chronic cerebral ischemia, among which atherosclerosis, hypertension, myocardial diseases, diabetes mellitus, etc. play a major role. The main clinical manifestations of this disease are described. The emphasis is on the fact that the main nucleus of the clinical picture of chronic cerebral ischemia is cognitive impairment, which in most cases determines the severity of patients. The development of cognitive impairment is associated with focal or diffuse brain lesions, resulting in the impairment of one or more cognitive functions. Vascular cognitive deficits are the result of acute or chronic cerebrovascular processes. The main causes and mechanisms of vascular cognitive impairment development are presented. It is shown that depending on the mechanism and the cause, the rate of cognitive impairment development may vary. The clinical picture of cognitive impairments developing as a result of the lesion of small brain vessels is described. The peculiarities of vascular cognitive disorders occurring against the background of cerebral hypoperfusion are described. The modern criteria of diagnosis are given. The main diagnostic methods are listed. The main approaches in treatment of patients with chronic cerebral ischemia depending on the disease stage are described. In-depth attention is given to neuroprotection with a more detailed description of the mechanisms of action and clinical efficacy of drugs with active substances - citicoline and ethylmethylhydroxypyridine succinate.

1. Pizova N.V. Chronic cerebrovascular diseases: pathogenetic mechanisms, clinical manifestations, and approaches to therapy. Nevrologiya, neiropsikhi a-triya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):83-89. (In Russ.) doi: 10.14412/2074-2711-2018-1-83-89.

2. Gusev E.I., Konovalov A.N, Gekht A.B. (ed.). Neurology. National Guide. Brief edition. Moscow: GEOTAR-Media; 2018. 688 p. (In Russ.) Available at: https://vrachirf.ru/storage/7b/da/77/de/e9/76/4a/ad/4bd3-f6593c-6116cd.pdf.

3. Gusev E.I. Chukanova E.I., Chukanova A.S. Chronic cerebrovascular insufficiency. Moscow: Meditsina; 2019. 190 p. (In Russ.)

4. Xu W.L., Qiu C.X., Wahlin A., Winblad B., Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project. A 6-year follow-up study. Neurology. 2004;63(7):1181-1186. doi: 10.1212/01.wnl.0000140291.86406.d1.

5. O'Brien J.T., Erkinjuntti T., Reisberg B., Roman G., Sawada T., Pantoni L. et al. Vascular cognitive impairment. Lancet Neurology. 2003;2(2):89-98. doi: 10.1016/s1474-4422(03)00305-3.

6. Voskresenskaya O.N., Zakharova N.B., Tarasova Yu.S. et al. Possible mechanisms of cognitive dysfunction in patients with chronic forms of cerebrovascular diseases. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psichosomatics. 2018;10(1):32-36. (In Russ.) doi: 10.14412/2074-2711-2018-1-32-36.

7. Sachdev P.S., Brodaty H., Valenzuela M.J., Lorentz L., Looi J.C., Wen W., Zagami A.S. The neuropsyhological profile of vascular cognitive impairment in stroke and TIA patients. Neurology. 200423;62(6):912-919. doi: 10.1212/01.wnl.0000115108.65264.4b.

8. Erkinjuntti T., Roman G., Gauthier S., Feldman H., Rockwood K. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke. 2004;35(4):1010-1017. doi: 10.1161/01.STR.0000120731.88236.33.

9. Zakharov V.V., YAkhno N.N. Memory violations. Moscow: GEOTAR-Med; 2003. 158 p.

10. Parfenov V.A. Vascular cognitive impairment and chronic cerebral ischemia (dyscirculatory encephalopathy). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psichosomatics. 2019;11(3S):61-67. (In Russ.) doi: 10.14412/2074-2711-2019-3S-61-67.

11. Dadasheva M.N., Podrezova L.A., Shuchalin O.G. et al. Algorithm of therapy of distsirkulyatorny encephalopathy at patients with arterial hypertension in the general medical practice. RMGH = RMJ. 2009;(20):1320-1324. (In Russ.) Available at: https://www.rmj.ru/articles/nevrologiya/Algoritm_terapii_dis-cirkulyatornoy__encefalopatii_u_bolynyh_s_arterialynoy__gipertenziey_v_obschey_vrachebnoy_praktike/

12. Kadykov A.S., SHakhparonova N.V. Brain vascular diseases. Moscow: Miklosh; 2006, 192 p.

13. Luriya A.R. The highest cortical functions of the person and their violation at local damages of a brain. 2nd ed. Moscow: Izd-vo MGU; 1969. 504 p. (In Russ.)

14. Larrabee G.J., Crook T.M. Estimated prevalence of age associated memory impairment derived from standardized tests of memory function. Int Psychogeriatr. 1994;6(1):95-104. doi: 10.1017/s1041610294001663.

15. Shmidt E.V. Classification of vascular lesions of the brain and spinal cord. Zhurnal nevropatologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 1985;(9):1281-1288. (In Russ.)

16. Parfenov V.A. Diagnosis and treatment of chronic cerebrovascular disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2016;8(3):4-9. doi: 10.14412/2074-2711-2016-3-4-9.

17. Levine D.A., Langa K.M. Vascular cognitive impairment: disease mechanisms and therapeutic implications. Neurotherapeutics. 2011;8(3):361-373. doi: 10.1007/s13311-011-0047-z.

18. Gorelick P.B., Scuteri A., Black S.E. et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672-2713. doi: 10.1161/STR.0b013e3182299496.

19. Levin O.S. Cognitive violations in practice of the neurologist. Moscow; 2006.

20. Cherdak M.A., Parfenov V.A. The cognitive impairments in patients after ischemic stroke. Nevrologicheskii zhurnal = The Neurological Journal. 2011;16(6):37-44. (In Russ.) Available at: https://elibrary.ru/item.asp?id=17288456.

21. Palmer K., Wang H.X., Backman L., Winblad B., Fratiglioni L. Differential evolution of cognitive impairment in nondemented older persons. Am J Psychiatry. 2002;159(3):436-442. doi: 10.1176/appi.ajp.159.3.436.

22. Pizova N.V. Outpatient management after severe stroke with dementia. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;5(4):78-83. (In Russ.) doi: 10.14412/2074-27112013-2460.

23. Dainikova E., Pizova N. Cognitive reserve and cognitive impairments: drug and nondrug treatments. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(2S):62-68. (In Russ.) doi: 10.14412/2074-2711-2014-2S-62-68.

24. Vakhnina NV. Vascular cognitive impairment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;(1):74-79. (In Russ.) doi: 10.14412/2074-2711-2014-1-74-79.

25. Glodzik L., Rusinek H., Brys M., Tsui W.H., Switalski R., Mosconi L. et al. Framingham cardiovascular risk profile correlates with impaired hippocampal and cortical vasoreactivity to hypercapnia. J Cereb Blood Flow Metab. 2011;31(2):671-679. doi: 10.1038/jcbfm.2010.145.

26. Pizov A.V., Pizov N.A., Skachkova O.A., Pizovа N.V. Endothelial function in normal and pathological conditions. Meditsinskiy sovet = Medical Council. 2019;(6):154-159. (In Russ.) doi: 10.21518/2079-701X-2019-6-154-159.

27. Nasreddine Z.S., Phillips N.A., Bedirian V., Charbonneau S. et al. The Montreal Cognitive Assessment (MoCA): A brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699. doi: 10.1111/j.1532-5415.2005.53221.x.

28. Folstein M.F., Folstein S.E., McHugh P.R. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi: 10.1016/0022-3956(75)90026-6.

29. Dubois B., Slachevsky A., Litvan I., Pillon B. The FAB: a frontal assessment battery at bedside. Neurology. 2000;55(11):1621-1626. doi: 10.1212/WNL.55.11.1621.

30. Reitan R.M. Validity of the Trail Making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271-276. doi: 10.2466/pms.1958.8.3.271.

31. Sunderland T., Hill J.L., Mellow A.M., Lawlor B.A., Gundersheimer J., Newhouse P.A., Grafman J.H. Clock drawing in Alzheimer's disease: a novel measure of dementia severity. J Am Geriatr Soc. 1989;37(8):725-729. doi: 10.1111/j.1532-5415.1989.tb02233.x.

32. Wechsler D.A. Standardized memory scale for clinical use. J Psychol. 1945;19(1):87-95. doi: 10.1080/00223980.1945.9917223.

33. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457-507. doi: 10.1159/000131083.

34. Ginsberg M.D. Current status of neuroprotection for cerebral ischemia. Synoptic overview. Stroke. 2009;40(3_suppl_1):S111-S114. doi: 10.1161/STROKEAHA.108.528877.

35. Gusev E.I., Skvortsova V.I. Cerebral ischemia. Moscow: Medicine; 2001. 327 p.

36. Kaduszkiewicz H., Zimmermann T., Beck-Bornholdt H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomized clinical trials. BMJ. 2005;331(7512):321-327. doi: 10.1136/bmj.331.7512.321.

37. Pizov A.V., Pizov N.A., Skachkova O.A., Pizova N.V. Endothelial dysfunction as early predictor of atherosclerosis. Medical Alphabet. 2019;4(35):28-33. (In Russ.) doi: 10.33667/2078-5631-2019-4-35(410)-28-33.

38. Piradov M.A., Tanashyan M.M., Domashenko M.A., Maksimova M.Yu. Neuroprotection in cerebrovascular diseases: is it the search for life on Mars or a promising trend of treatment? Part 2. Chronic cerebrovascular diseases. Annaly klinicheskoy i eksperimental'noy nevrologii = Annals of Clinical and Experimental Neurology. 2015;9(3):10-19. (In Russ.) Available at: https://elibrary.ru/item.asp?id=25435162.

39. Kennedy E.P. The synthesis of cytidine diphosphate choline, cytidine diphosphate ethanolamine, and related compounds. J Biol Chem. 1956;222(1):185-191. Available at: https://jbc.org/content/222/1/185.long.

40. Adibhatla R.M., Hatcher J.F. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res. 2002;70(2):133-139. doi: 10.1002/jnr.10403.

41. Garda-Cobos R., Frank-Garcia A., Gutierrez-Fernandez M., D^ez-Tejedor E. Citicoline, use in cognitive decline: Vascular and degenerative. J. Neurol. Sci. 2010;299(1-2):188-192. doi: 10.1016/j.jns.2010.08.027.

42. Fioravanti M., Yanagi M. Cytidinediphosphocholine (CDPcholine) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;(2):CD000269. doi: 10.1002/14651858.CD000269.pub3.

43. Maximova M.Yu., Piradov M.A. Syndrome of insufficiency of blood flow in arteries of vertebrobasilar system. RMGH = RMJ. 2018;(7):4-8. (In Russ.) Available at: https://www.rmj.ru/articles/nevrologiya/Sindrom_nedostat-ochnosti_krovotoka_varteriyah_vertebrobazilyarnoy_sistemy/

44. Khazanov V.A. Pharmacologycal regulation of energy metabolism. Ehksperimental'naya i klinicheskaya farmakologiya = Experimental and Clinical Pharmacology. 2009;72(4):61-64. (In Russ.) doi: 10.30906/08692092-2009-72-4-61-64.

45. Voronina T.A. Mexidol: the spectrum of pharmacological effects. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(12):86-90. (In Russ.) Available at: https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2012/12/031997-729820121215.

46. Afanasiev V.V., Rumiantseva S.A., Stupin V.A. et al. Complex neurocytoprotec-tion in the aspect of pharmacodynamics. Zhurnal Nevrologii im. B.M. Man'kovs'kogo = The Journal of Neuroscience. 2017;5(3-4):13-27. (In Russ.) Available at: https://neuroscience.com.ua/index.php/journal/article/view/69.

47. Burchinskiy S.G.. Neuroprotection as a complex pharmacotherapeutic and pharmacoprophylactic strategy. Therapia. 2008;(2):53-56.

48. Liang O.V., Kochetov A.G. The use of mexidol in chronic cerebral ischemia. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(12):126-129. (In Russ.) Available at: https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2013/12/031997-729820131223/annotation.

49. Gromova O.A., Torshin I.Yu., Stelmashuk E.V., Alexandrova O.P., Pronin A.V., Gogoleva I.V., Haspekov L.G. A study of the neuroprotective effect of mex-idol on the cell model of glutamate stress. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2017;117(12):71-77. (In Russ.) doi: 10.17116/jnevro201711712171-77.

50. Rumyantseva S.A., Fedin A.I., Sokhova O.N. Antioxidant therapy of ischemic brain lesions. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2011;(4 вып. 2):28-31. (In Russ.) Available at: https://mexidol.ru/files/2011_4__.pdf

51. Mayorova N.G., Pavlov V.A. Clinical experience with Neurox used in patients with cerebrovascular disease. Nevrologiya, neyropsikhiatriya, psik-hosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(1):71-74. (In Russ.) doi: 10.14412/2074-2711-2011-138.

52. Gromova O.A., Torshin I.Yu., Stakhovskaya L.V., Pepelyaev E.G., Semenov V.A., Nazarenko A.G. Experience with mexidol in neurological practice. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(10):97-107. (In Russ.) doi: 10.17116/jnevro201811810197.

53. Solovyeva E.Yu., Karneev A.N., Chekanov A.V., Baranova O.A. The individual and combined antioxidant effects of citicoline and ethylmethylhy-droxypyridini succinas. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(11):78-85. doi: 10.17116/jnevro201611611178-85.

54. Soloveva E.Yu., Amelina I.P. Cerebral small vessel disease's impact on the development of chronic cerebral ischemia: paradigms of the treatment. Meditsinskiy sovet = Medical Council. 2020;(2):16-24. (In Russ.) doi: 10.21518/2079-701X-2020-2-16-24.